Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Growth factors for therapeutic angiogenesis in cardiovascular diseases
Autore:
Vale, PR; Losordo, DW; Symes, JF; Isner, JM;
Indirizzi:
Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med Vasc, Boston, MA 02135 USA Tufts Univ Boston MA USA 02135 d Ctr, Dept Med Vasc, Boston, MA 02135 USA Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Cardiol, Boston, MA 02135USA Tufts Univ Boston MA USA 02135 Med Ctr, Dept Cardiol, Boston, MA 02135USA Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Cardiothorac Surg, Boston, MA 02135 USA Tufts Univ Boston MA USA 02135 pt Cardiothorac Surg, Boston, MA 02135 USA
Titolo Testata:
REVISTA ESPANOLA DE CARDIOLOGIA
fascicolo: 10, volume: 54, anno: 2001,
pagine: 1210 - 1224
SICI:
0300-8932(200110)54:10<1210:GFFTAI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
SPA
Soggetto:
ENDOTHELIAL PROGENITOR CELLS; ARTERIAL GENE-TRANSFER; CHRONIC MYOCARDIAL-ISCHEMIA; REFRACTORY ANGINA-PECTORIS; TRANSMYOCARDIAL LASER REVASCULARIZATION; COLLATERAL BLOOD-FLOW; NAKED DNA; IN-VIVO; TRANSENDOCARDIAL INJECTION; INTRAMYOCARDIAL DELIVERY;
Keywords:
myocardial ischemia; peripheral arterial disease; VEGF; FGF; gene transfer;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
109
Recensione:
Indirizzi per estratti:
Indirizzo: Isner, JM Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med Vasc, 736 Cambridge St, Boston, MA 02135 USA Tufts Univ 736 Cambridge St Boston MA USA02135 on, MA 02135 USA
Citazione:
P.R. Vale et al., "Growth factors for therapeutic angiogenesis in cardiovascular diseases", REV ESP CAR, 54(10), 2001, pp. 1210-1224

Abstract

Therapeutic angiogenesis based on the administration of growth factors with angiogenic activity allows enhancement of collateral vessels able to palliate insufficient tissue perfusion secondary to obstruction of native arteries. At present, this type of therapy is addressed to patients that fall torespond to conventional treatment (surgical or percutaneous revascularization). The most extensively investigated angiogenic growth factors are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). These cytokines can be administered either as recombinant proteins or as the genes encoding for these proteins. Both approaches have pros and cons that are under investigation in animal models and in clinical studies. Although clinical trials consist so far of small, often non-randomized series, preliminary results are promising. For example, administration of VEGF or FGF has been associated to objective evidence of increased tissue perfusion in patients with myocardial ischemia, and to a. significant improvement of pain and Ischemia in patients with peripheral arterial disease. Contrarily to expected, these interventions have been associated to scant adverse side effects, although larger clinical trials will be necessary in order to prove the safety and effectiveness of these interventions. Nevertheless, it seems clear that it is feasible to induce effective therapeutic angiogenesis in selected patients without significant associated toxicity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 19:54:12